Welcome to our dedicated page for Corcept Therapeutics SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics’ Chief Development Officer William Guyer reported an exercise-and-sell transaction in company stock. He exercised options to acquire 20,000 shares of common stock at a price of $21.65 per share, then sold 20,000 shares at a weighted average price of $70.60 per share in an open-market transaction.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 3,985 shares of common stock and stock options for 150,000 shares that are fully exercisable, along with additional unvested restricted stock awards scheduled to vest one year after their respective grant dates.
Corcept Therapeutics officer Joseph Douglas Lyon reported routine equity compensation and related tax withholding transactions. On June 1, 2026, he acquired 537 shares of common stock at $0.00 per share as a grant or award, and a separate 537-share acquisition was priced at $70.44 per share under a purchase plan tied to the closing price that day. On June 2, 2026, 269 shares were withheld by Corcept at $70.44 per share to satisfy tax obligations on vesting restricted stock units. After these transactions, he directly held 7,035 common shares, including unvested restricted stock that will vest on one-year anniversaries of their grant dates if conditions are met.
Corcept Therapeutics Chief Development Officer William Guyer reported stock-based compensation and share purchases in company stock. On June 1, 2026, he acquired 877 shares of common stock as a grant at $0.00 per share and an additional 877 shares at $70.44 per share under a purchase plan established within the 2024 Incentive Award Plan. Footnotes show these include shares underlying unvested restricted stock awards, which vest in full one year after their grant dates if service and ownership conditions are met.
Corcept Therapeutics (CORT) officer Sean Maduck reported a series of equity transactions involving company common stock. He exercised stock options for 25,000 shares at $8.27 per share and on the same date sold 25,000 shares in open-market transactions at weighted average prices of about $70–71 per share under a pre-arranged Rule 10b5-1 trading plan. The company also withheld 452 shares valued at $70.44 per share to cover tax obligations on vesting of restricted stock units, which is not an open-market sale. Following these transactions, Maduck holds 9,755 shares directly, plus indirect interests including 10,000 shares in a living trust, 34,000 in MMM 2025, LLC, 40,000 and 20,570 shares in two Grantor Retained Annuity Trusts, and 5,147 shares in Duckhill Capital, LLC, where he disclaims beneficial ownership beyond his pecuniary interest.
Corcept Therapeutics Chief Financial Officer Atabak Mokari reported a set of equity transactions in the company’s common stock. On June 1, 2026, he exercised stock options to acquire 40,000 shares at an exercise price of $19.26 per share, then sold the same 40,000 shares in an open-market transaction at a weighted average price of about $70.00 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. He also received stock awards totaling 634 shares at no cost and an additional 634 shares tied to a purchase plan, while 395 shares were withheld to satisfy tax obligations related to vested restricted stock units. Following these transactions, he directly holds 16,130 shares of common stock, plus unvested restricted stock awards that vest on future one-year anniversaries, subject to continued service and other conditions.
Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported routine equity compensation and related tax withholding in common stock. On June 1, 2026, he acquired 776 shares under a purchase plan established within the 2024 Incentive Award Plan, with the price based on the closing price that day. The filing also notes restricted stock awards that vest after one year if specific service or ownership conditions are met. On June 2, 2026, 358 shares were withheld by the company at $70.44 per share to satisfy tax obligations tied to vesting restricted stock units, leaving him with 25,681 directly held shares. Additional common stock is held indirectly through a revocable trust and custodial accounts for his children.
Corcept Therapeutics’ Chief Executive Officer, Joseph K. Belanoff, reported a mix of open-market sales and estate-planning transfers involving the company’s common stock. An entity associated with him, the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust, sold 12,837 shares at $69.74 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan, leaving 2,565,489 shares held by that trust.
Separately, there were gift transfers totaling 600,000 shares with no consideration. These included 300,000 shares transferred out of the revocable living trust, and 150,000 shares to each of two 2026 Grantor Retained Annuity Trusts for Joseph K. Belanoff and for his spouse, respectively. The filing notes that the CEO disclaims beneficial ownership of certain trust-held shares except to the extent of his pecuniary interest.
Corcept Therapeutics Inc. reported proposed sales of common stock by an affiliate under a Form 144 notice. The filing lists a 20,000-share sale associated with a stock option exercise on 06/02/2026 and several prior dispositions in March–May 2026.
The filings show prior reported sales of 20,000 shares on 04/08/2026 for $819,453.00, 8,233 shares on 03/04/2026 for $296,346.00, 11,767 shares on 03/20/2026 for $423,707.00, and 20,000 shares on 05/06/2026 for $1,036,522.00. The broker listed is Stifel Nicolaus & Company Inc.
CORT files a Rule 144 notice to sell 160,000 shares of Common Stock through Stifel Nicolaus & Company Inc. The filing references 160,000 shares, an amount of $11,200,016.00, and a Nasdaq listing with a date entry of 06/01/2026. The excerpt also lists prior stock option exercises of 95,833 (02/02/2022) and 64,167 (02/13/2023).